Drug intelligence / Profile preview

iPLTs-02

Development stage: Preclinical
Lead developer: HemaCell Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iPLTs-02 is an induced pluripotent stem cell (iPSC)-derived platelet cell therapy developed by HemaCell Therapeutics (also known as Xue Ji Bio). The product is designed to treat thrombocytopenia, a condition characterized by low platelet counts that can lead to impaired blood clotting and increased risk of bleeding. The therapy involves the administration of functional platelets differentiated from iPSCs, offering a potential alternative to traditional donor-derived platelet transfusions. This approach aims to provide a more consistent, scalable, and potentially safer supply of platelets for patients. iPLTs-02 is currently in the preclinical stage of development.

Other names: iPSC-derived platelet product

Beyond the preview

Go deeper on iPLTs-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPLTs-02.

Explore the full profile